Imaging agent developer ImaginAb said data from the first-in-human imaging study of its CD8 T-cell PET agent for use in detecting solid malignancies were published online October 4 in the Journal of Nuclear Medicine.
The research showed that ImaginAb's CD8 zirconium-89 (Zr-89) IAB22M2C agent was well tolerated with no immediate or delayed side effects, according to the firm. The biodistribution of the agent also suggested that CD8+ T cell-rich tissues were successfully targeted. The observed targeting of tumor lesions indicates the agent may be helpful for assessing the accumulation of CD8+ T cells within tumors, the company said.
The tracer is currently in phase II clinical trials.
